{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:01:59Z","timestamp":1784354519794,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04350-x","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T09:32:04Z","timestamp":1772703124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblasts"],"prefix":"10.1007","volume":"75","author":[{"given":"Ryo","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0041-6981","authenticated-orcid":false,"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Shono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Sekiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kushiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Yanagimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Saida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hokari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riuko","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"4350_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"4350_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/intimm\/dxu095","volume":"27","author":"GK Philips","year":"2015","unstructured":"Philips GK, Atkins M (2015) Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 27:39\u201346. https:\/\/doi.org\/10.1093\/intimm\/dxu095","journal-title":"Int Immunol"},{"key":"4350_CR3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr., Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"key":"4350_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"4350_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"4350_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"4350_CR7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"4350_CR8","doi-asserted-by":"publisher","first-page":"e001223","DOI":"10.1136\/jitc-2020-001223","volume":"8","author":"L Cassetta","year":"2020","unstructured":"Cassetta L, Bruderek K, Skrzeczynska-Moncznik J et al (2020) Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. J Immunother Cancer 8:e001223. https:\/\/doi.org\/10.1136\/jitc-2020-001223","journal-title":"J Immunother Cancer"},{"key":"4350_CR9","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1158\/1078-0432.Ccr-23-0219","volume":"29","author":"C Pich-Bavastro","year":"2023","unstructured":"Pich-Bavastro C, Yerly L, Di Domizio J, Tissot-Renaud S, Gilliet M, Kuonen F (2023) Activin A-mediated polarization of cancer-associated fibroblasts and macrophages confers resistance to checkpoint immunotherapy in skin cancer. Clin Cancer Res 29:3498\u20133513. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-0219","journal-title":"Clin Cancer Res"},{"key":"4350_CR10","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.4049\/jimmunol.181.5.3291","volume":"181","author":"S Watanabe","year":"2008","unstructured":"Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, Cohen PA, Shu S (2008) Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol 181:3291\u20133300. https:\/\/doi.org\/10.4049\/jimmunol.181.5.3291","journal-title":"J Immunol"},{"key":"4350_CR11","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","volume":"72","author":"AM Lesokhin","year":"2012","unstructured":"Lesokhin AM, Hohl TM, Kitano S et al (2012) Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 72:876\u2013886. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1792","journal-title":"Cancer Res"},{"key":"4350_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/0008-5472.CAN-23-1448","volume":"84","author":"C Li","year":"2024","unstructured":"Li C, Guo H, Zhai P et al (2024) Spatial and single-cell transcriptomics reveal a cancer-associated fibroblast subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells. Cancer Res 84:258\u2013275. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1448","journal-title":"Cancer Res"},{"key":"4350_CR13","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1038\/s41467-020-19408-2","volume":"11","author":"M Desbois","year":"2020","unstructured":"Desbois M, Udyavar AR, Ryner L et al (2020) Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nat Commun 11:5583. https:\/\/doi.org\/10.1038\/s41467-020-19408-2","journal-title":"Nat Commun"},{"key":"4350_CR14","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang J, Yan J, Liu B (2018) Targeting VEGF\/VEGFR to modulate antitumor immunity. Front Immunol 9:978. https:\/\/doi.org\/10.3389\/fimmu.2018.00978","journal-title":"Front Immunol"},{"key":"4350_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","volume":"38","author":"M Katoh","year":"2016","unstructured":"Katoh M (2016) FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review). Int J Mol Med 38:3\u201315. https:\/\/doi.org\/10.3892\/ijmm.2016.2620","journal-title":"Int J Mol Med"},{"key":"4350_CR16","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.2174\/13816128113199990592","volume":"20","author":"C Gialeli","year":"2014","unstructured":"Gialeli C, Nikitovic D, Kletsas D, Theocharis AD, Tzanakakis GN, Karamanos NK (2014) PDGF\/PDGFR signaling and targeting in cancer growth and progression: focus on tumor microenvironment and cancer-associated fibroblasts. Curr Pharm Des 20:2843\u20132848. https:\/\/doi.org\/10.2174\/13816128113199990592","journal-title":"Curr Pharm Des"},{"key":"4350_CR17","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V (2018) Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol 9:1310. https:\/\/doi.org\/10.3389\/fimmu.2018.01310","journal-title":"Front Immunol"},{"key":"4350_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D (2018) Myeloid-derived suppressor cells coming of age. Nat Immunol 19:108\u2013119. https:\/\/doi.org\/10.1038\/s41590-017-0022-x","journal-title":"Nat Immunol"},{"key":"4350_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12392","volume":"43","author":"Z Fang","year":"2023","unstructured":"Fang Z, Meng Q, Xu J et al (2023) Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. Cancer Commun 43:3\u201341. https:\/\/doi.org\/10.1002\/cac2.12392","journal-title":"Cancer Commun"},{"key":"4350_CR20","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071\u20132082. https:\/\/doi.org\/10.1056\/NEJMoa1402584","journal-title":"N Engl J Med"},{"key":"4350_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143\u2013155. https:\/\/doi.org\/10.1016\/S1470-2045(13)70586-2","journal-title":"Lancet Oncol"},{"key":"4350_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150735","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Huang H, Coleman M, Ziemys A, Gopal P, Kazmi SM, Brekken RA (2021) VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.150735","journal-title":"JCI Insight"},{"key":"4350_CR23","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4350_CR24","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/cas.13580","volume":"109","author":"H Krishnan","year":"2018","unstructured":"Krishnan H, Rayes J, Miyashita T et al (2018) Podoplanin: an emerging cancer biomarker and therapeutic target. Cancer Sci 109:1292\u20131299. https:\/\/doi.org\/10.1111\/cas.13580","journal-title":"Cancer Sci"},{"key":"4350_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/S13059-015-0620-6","volume":"16","author":"M Angelova","year":"2015","unstructured":"Angelova M, Charoentong P, Hackl H et al (2015) Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol 16:64. https:\/\/doi.org\/10.1186\/S13059-015-0620-6","journal-title":"Genome Biol"},{"key":"4350_CR26","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1084\/jem.20170724","volume":"214","author":"DE Kim","year":"2017","unstructured":"Kim DE, Procopio MG, Ghosh S et al (2017) Convergent roles of ATF3 and CSL in chromatin control of cancer-associated fibroblast activation. J Exp Med 214:2349\u20132368. https:\/\/doi.org\/10.1084\/jem.20170724","journal-title":"J Exp Med"},{"key":"4350_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1158\/0008-5472.Can-08-2724","volume":"69","author":"C Anderberg","year":"2009","unstructured":"Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, Eriksson U, Pietras K (2009) Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 69:369\u2013378. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-2724","journal-title":"Cancer Res"},{"key":"4350_CR28","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/cas.12745","volume":"106","author":"YP Bai","year":"2015","unstructured":"Bai YP, Shang K, Chen H, Ding F, Wang Z, Liang C, Xu Y, Sun MH, Li YY (2015) FGF-1\/-3\/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7. Cancer Sci 106:1278\u20131287. https:\/\/doi.org\/10.1111\/cas.12745","journal-title":"Cancer Sci"},{"key":"4350_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"4350_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571. https:\/\/doi.org\/10.1038\/nature13954","journal-title":"Nature"},{"key":"4350_CR31","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M et al (2017) IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930\u20132940. https:\/\/doi.org\/10.1172\/JCI91190","journal-title":"J Clin Invest"},{"key":"4350_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E (2019) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov 18:99\u2013115. https:\/\/doi.org\/10.1038\/s41573-018-0004-1","journal-title":"Nat Rev Drug Discov"},{"key":"4350_CR33","doi-asserted-by":"publisher","first-page":"1152934","DOI":"10.3389\/fphar.2023.1152934","volume":"14","author":"J Zhai","year":"2023","unstructured":"Zhai J, Gu X, Liu Y, Hu Y, Jiang Y, Zhang Z (2023) Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Front Pharmacol 14:1152934. https:\/\/doi.org\/10.3389\/fphar.2023.1152934","journal-title":"Front Pharmacol"},{"key":"4350_CR34","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/s41467-019-09415-3","volume":"10","author":"P Liu","year":"2019","unstructured":"Liu P, Zhao L, Pol J et al (2019) Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun 10:1486. https:\/\/doi.org\/10.1038\/s41467-019-09415-3","journal-title":"Nat Commun"},{"key":"4350_CR35","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares N, Pequignot MO, Tesniere A et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691\u20131701. https:\/\/doi.org\/10.1084\/jem.20050915","journal-title":"J Exp Med"},{"key":"4350_CR36","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1186\/s12885-021-08974-3","volume":"21","author":"Y Sato","year":"2021","unstructured":"Sato Y, Fu Y, Liu H, Lee MY, Shaw MH (2021) Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. BMC Cancer 21:1222. https:\/\/doi.org\/10.1186\/s12885-021-08974-3","journal-title":"BMC Cancer"},{"key":"4350_CR37","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH et al (2018) Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity 49:1148\u201361.e7. https:\/\/doi.org\/10.1016\/j.immuni.2018.09.024","journal-title":"Immunity"},{"key":"4350_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc.2017.117","volume":"18","author":"S Spranger","year":"2018","unstructured":"Spranger S, Gajewski TF (2018) Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer 18:139\u2013147. https:\/\/doi.org\/10.1038\/nrc.2017.117","journal-title":"Nat Rev Cancer"},{"key":"4350_CR39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.Can-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, Pernot S, Marcheteau E et al (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73:539\u2013549. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-2325","journal-title":"Cancer Res"},{"key":"4350_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fimmu.2013.00483","volume":"4","author":"G Schiavoni","year":"2013","unstructured":"Schiavoni G, Mattei F, Gabriele L (2013) Type I interferons as stimulators of DC-mediated cross-priming: Impact on anti-tumor response. Front Immunol 4:483. https:\/\/doi.org\/10.3389\/fimmu.2013.00483","journal-title":"Front Immunol"},{"key":"4350_CR41","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K (2022) Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer 21:184. https:\/\/doi.org\/10.1186\/s12943-022-01657-y","journal-title":"Mol Cancer"},{"key":"4350_CR42","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1158\/2326-6066.CIR-15-0298","volume":"4","author":"K Tada","year":"2016","unstructured":"Tada K, Kitano S, Shoji H et al (2016) Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. Cancer Immunol Res 4:592\u2013599. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0298","journal-title":"Cancer Immunol Res"},{"key":"4350_CR43","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-15-0193","volume":"4","author":"J Weber","year":"2016","unstructured":"Weber J, Gibney G, Kudchadkar R et al (2016) Phase I\/II study of metastatic melanoma patients treated with nivolumab who had progressed after Ipilimumab. Cancer Immunol Res 4:345\u2013353. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0193","journal-title":"Cancer Immunol Res"},{"key":"4350_CR44","doi-asserted-by":"publisher","first-page":"55804","DOI":"10.18632\/oncotarget.18437","volume":"8","author":"PE Clavijo","year":"2017","unstructured":"Clavijo PE, Moore EC, Chen J, Davis RJ, Friedman J, Kim Y, Van Waes C, Chen Z, Allen CT (2017) Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. Oncotarget 8:55804\u201355820. https:\/\/doi.org\/10.18632\/oncotarget.18437","journal-title":"Oncotarget"},{"key":"4350_CR45","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/s41467-017-00784-1","volume":"8","author":"J Zhu","year":"2017","unstructured":"Zhu J, de Tenbossche CGP, Can\u00e9 S et al (2017) Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nat Commun 8:1404. https:\/\/doi.org\/10.1038\/s41467-017-00784-1","journal-title":"Nat Commun"},{"key":"4350_CR46","doi-asserted-by":"publisher","first-page":"e158661","DOI":"10.1172\/JCI158661","volume":"132","author":"SH Colligan","year":"2022","unstructured":"Colligan SH, Amitrano AM, Zollo RA et al (2022) Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression. J Clin Invest 132:e158661. https:\/\/doi.org\/10.1172\/JCI158661","journal-title":"J Clin Invest"},{"key":"4350_CR47","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang MM, Coupland SE, Aittokallio T, Figueiredo CR (2023) Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br J Cancer 129:1212\u20131224. https:\/\/doi.org\/10.1038\/s41416-023-02361-4","journal-title":"Br J Cancer"},{"key":"4350_CR48","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","volume":"82","author":"L Jenkins","year":"2022","unstructured":"Jenkins L, Jungwirth U, Avgustinova A, Iravani M, Mills A, Haider S, Harper J, Isacke CM (2022) Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res 82:2904\u20132917. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4141","journal-title":"Cancer Res"},{"key":"4350_CR49","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41416-020-01201-z","volume":"124","author":"R Kato","year":"2021","unstructured":"Kato R, Haratani K, Hayashi H et al (2021) Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. Br J Cancer 124:914\u2013924. https:\/\/doi.org\/10.1038\/s41416-020-01201-z","journal-title":"Br J Cancer"},{"key":"4350_CR50","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41416-020-0744-7","volume":"122","author":"T Yamanaka","year":"2020","unstructured":"Yamanaka T, Harimoto N, Yokobori T et al (2020) Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts. Br J Cancer 122:986\u2013994. https:\/\/doi.org\/10.1038\/s41416-020-0744-7","journal-title":"Br J Cancer"},{"key":"4350_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006130","author":"YE Lee","year":"2023","unstructured":"Lee YE, Go GY, Koh EY et al (2023) Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-006130","journal-title":"J Immunother Cancer"},{"key":"4350_CR52","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/S13046-022-02423-0","volume":"41","author":"C Baldini","year":"2022","unstructured":"Baldini C, Danlos FX, Varga A et al (2022) Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. J Exp Clin Cancer Res 41:217. https:\/\/doi.org\/10.1186\/S13046-022-02423-0","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04350-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04350-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04350-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T09:32:06Z","timestamp":1772703126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04350-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4350"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04350-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal studies were approved by the Niigata University Institutional Animal Care and Use Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"94"}}